Wolfe Research analyst Rudy Li initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $230 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” On Axsome specifically, the firm cited a positive view of lead asset Auvelity.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $215 from $195 at TD Cowen
- Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx
- Axsome Therapeutics: Buy Rating on Solid Execution, Sufficient Cash Runway, and Advancing Late‑Stage Pipeline
- Buy Rating on Axsome: Strong Commercial Momentum, Expanding CNS Pipeline, and Attractive Valuation Upside
- Axsome Therapeutics reports Q4 EPS (56c), consensus (73c)